Glycopeptides

Subscribe to Selected New Research on Glycopeptides

500 relevant articles (25 outcomes, 36 trials/studies) found for this Bio-Agent

Description: Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight.

Relationship Network

Bio-Agent Context: Research Results

fibroblast proliferation inhibitor: 3

polyactin A: 3

suppressor active peptide (thermal injury): 3

galactosyltransferase acceptor: 2

ovoglycopeptide: 2

sleep-promoting factor B: 2

di-N-acetylchitobiosyl poly(L-asparagine): 1

galactomannane peptide: 1

human pituitary glycopeptide: 1

MIF A3: 1

peptidoglycolipids: 1

SK&F 104662: 1

WOG solution: 1

(3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methyl 2-((benzyloxy)carbonyl)amino-3-phenylpropanoate

(YEE(ah-GalNAc)3)-SMCC-AET-pU(m)pT(7)

1-O-methyl-2-N-(1'-(argininocarbonyl)-4'-((4''-fluoro)benzylamido)cyclohexane)glucosamine

2-acetamido-2-deoxygalactopyranosyl tuftsin

3-(4-(1-amino-2-(galactosylthio)ethyl-histidylamino)butylcarbamoyloxy)cholesterol

3-O-(2-acetamido-2-deoxygalactopyranosyl)-acetyl-threonyl-alanyl-alanine methyl ester

4-borono-2-fluorophenylalaninefructose

A 41030

A35512 antibiotic complex

carboxyeremomycin bis-benzylamide

egg yolk sialylglycopeptide

eremomycin cyclic covalent dimer

eremomycin pseudoaglycone

fluoresceinthiocarbamoyl-Lys-GlcNAc-1-4-MurNAc-Ala-isoglutamine

fluorobalhimycin

fungal gp8 glycopeptide

Glc-(1-4)-norMurNAc-Abu-isoGln

GlcNstearoyl-(1-4)-norMurNAc-Abu-isoGln

glycopeptide gp432

glycopeptide gp95

glycopeptide T1

glycotriosyl glutamine

hassallidin B

heptylglycoside-muramyldipeptide

human FSH-BI protein

human SPAG11A protein

IGG autoantibody binding determinant

izupeptin A

izupeptin B

kappa-casein glycomacropeptide

kappa-caseinoglycopeptide

mannopeptimycin glycopeptide

mannopeptimycin-E

mannopeptins

N',N''-dibenzyleremomycin

N(alpha)-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxygalactopyranosyl)serine pentafluorphenyl ester

N(alpha)-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxygalactopyranosyl)threonine pentafluorphenyl ester

N,N-dimethyl-O-(2-acetamido-2-deoxygalactopyranosyl)-(1-3)-O-(fucopyranosyl)-(1-2)-O-(galactopyranosyl)-(1-3)-O-(2-acetamido-2-deoxygalactopyranosyl)-(1-3)-serine

niacytin

O-Gal-Ser(5)- YFa peptide

O-Glu-Ser(5)- YFa peptide

O-glucopyranosyl-(1-6)-O-glucopyranosyl-(1-6)-1-N-(aspart-1-oyl-proline-4-oyl)glucopyranosylamine

Amino Acids, Peptides, and Proteins

Acetylmuramyl-Alanyl-Isoglutamine: 352

Ristocetin: 257

phosphoramidon: 104

Sialoglycoproteins: 82

fibroblast proliferation inhibitor: 3

polyactin A: 3

suppressor active peptide (thermal injury): 3

galactosyltransferase acceptor: 2

ovoglycopeptide: 2

sleep-promoting factor B: 2

di-N-acetylchitobiosyl poly(L-asparagine): 1

galactomannane peptide: 1

human pituitary glycopeptide: 1

MIF A3: 1

peptidoglycolipids: 1

SK&F 104662: 1

WOG solution: 1

(3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methyl 2-((benzyloxy)carbonyl)amino-3-phenylpropanoate

(YEE(ah-GalNAc)3)-SMCC-AET-pU(m)pT(7)

1-O-methyl-2-N-(1'-(argininocarbonyl)-4'-((4''-fluoro)benzylamido)cyclohexane)glucosamine

2-acetamido-2-deoxygalactopyranosyl tuftsin

3-(4-(1-amino-2-(galactosylthio)ethyl-histidylamino)butylcarbamoyloxy)cholesterol

3-O-(2-acetamido-2-deoxygalactopyranosyl)-acetyl-threonyl-alanyl-alanine methyl ester

4-borono-2-fluorophenylalaninefructose

A 41030

A35512 antibiotic complex

carboxyeremomycin bis-benzylamide

egg yolk sialylglycopeptide

eremomycin cyclic covalent dimer

eremomycin pseudoaglycone

fluoresceinthiocarbamoyl-Lys-GlcNAc-1-4-MurNAc-Ala-isoglutamine

fluorobalhimycin

fungal gp8 glycopeptide

Glc-(1-4)-norMurNAc-Abu-isoGln

GlcNstearoyl-(1-4)-norMurNAc-Abu-isoGln

glycopeptide gp432

glycopeptide gp95

glycopeptide T1

glycotriosyl glutamine

hassallidin B

heptylglycoside-muramyldipeptide

human FSH-BI protein

human SPAG11A protein

IGG autoantibody binding determinant

izupeptin A

izupeptin B

kappa-casein glycomacropeptide

kappa-caseinoglycopeptide

mannopeptimycin glycopeptide

mannopeptimycin-E

mannopeptins

N',N''-dibenzyleremomycin

N(alpha)-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxygalactopyranosyl)serine pentafluorphenyl ester

N(alpha)-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxygalactopyranosyl)threonine pentafluorphenyl ester

N,N-dimethyl-O-(2-acetamido-2-deoxygalactopyranosyl)-(1-3)-O-(fucopyranosyl)-(1-2)-O-(galactopyranosyl)-(1-3)-O-(2-acetamido-2-deoxygalactopyranosyl)-(1-3)-serine

niacytin

O-Gal-Ser(5)- YFa peptide

Experts

1.	Saba, Vittorio: 5 articles (04/2007 - 09/2002)
2.	Ghiselli, Roberto: 5 articles (04/2007 - 09/2002)
3.	Cirioni, Oscar: 5 articles (04/2007 - 09/2002)
4.	Giacometti, Andrea: 5 articles (04/2007 - 09/2002)
5.	Orlando, Fiorenza: 5 articles (04/2007 - 09/2002)
6.	Scalise, Giorgio: 5 articles (04/2007 - 09/2002)
7.	Mocchegiani, Federico: 5 articles (04/2007 - 09/2002)
8.	Papini, Anna Maria: 3 articles (09/2008 - 08/2006)
9.	Silvestri, Carmela: 3 articles (04/2007 - 10/2003)
10.	D'Amato, Giuseppina: 3 articles (08/2004 - 08/2003)

Related Diseases

1.	Infection 10/01/2007 - "CONCLUSIONS: The prophylactic use of glycopeptides in paediatric patients at high risk of MRSA infection undergoing cardiac surgery was safe and effective. " 03/01/2006 - "aureus resistance to glycopeptides did not emerge until nearly 40 years after their clinical introduction, and as a result this drug class has remained the mainstay of treatment for MRSA infections. " 12/01/2005 - "Recently, large randomized clinical trials and meta-analysis showed that the addition of an aminoglycoside and/or a glycopeptides results in a more favourable outcome only in selected severe infections. " 12/01/1997 - "Nevertheless, not enough many prospective-controlled studies have been carried on to evaluate whether glycopeptides reduce the risk of post-surgical infections, more than other conventional antibiotic regimens. " 01/17/1983 - "Immunostimulation with glycopeptides deserves further study in prophylaxis or therapy of fungal infection." Order ALL the reference details at left...
2.	Endocarditis 10/01/2001 - "Consequences of VanE-type resistance on efficacy of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecalis." 03/01/1997 - "The efficacy of glycopeptides against BM4281 was investigated in a rabbit model of experimental endocarditis for reduction of bacterial counts in cardiac vegetations and selection of mutants with increased resistance to glycopeptides. " 09/01/1998 - "CONCLUSIONS: Clinical data on the use of glycopeptides in endocarditis suffer from a lack of controlled trials. " 11/01/2003 - "Influence of VanD type resistance on activities of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecium." 07/01/1999 - "Glycopeptides have been recommended as therapy for endocarditis. " Order ALL the reference details at left...
3.	Neoplasms (Cancer) 01/01/2008 - "In the present study, the glycan profiles of free and complexed forms of PSA from cancer patient serum and of seminal plasma PSA were compared by analyzing the glycopeptides obtained by lysylendopeptidase digestion of the electrophoretically separated PSA with mass spectrometry. " 02/01/2007 - "Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. " 02/01/2006 - "Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance." 06/01/2003 - "Multi-component glycopeptide libraries and single glycopeptides were used for immunization of mice with the aim of inducing strong T helper cell responses to the repetitive sequence of MUC1 expressed by human tumor cells. " 12/01/2000 - "Synthesis of tumor associated sialyl-T-glycopeptides and their immunogenicity." Order ALL the reference details at left...
4.	Septic Shock (Toxic Shock Syndrome) 03/01/2006 - "There was no statistically significant difference in MRSA-related deaths between patients receiving glycopeptides before or within 48 h after blood culture (n = 43) (55%, 18/33, non-septic shock group; 90%, 9/10, septic shock group) or those whose glycopeptide therapy was begun more than 48 h after blood culture (n = 119) (37%, 40/107, non-septic shock group; 83%, 10/12, septic shock group) (P = 0.11 and 1.00, respectively). " 04/01/2003 - "An animal study was performed to investigate the efficacy of two glycopeptides and two cationic peptides in the prevention of lethality in a septic shock rat model. " 04/01/2007 - "In bivariate analyses, the following factors were statistically associated with higher mortality: rapidly fatal underlying disease, altered mental status, metabolic acidosis, and acute severe clinical condition at the onset of bacteraemia; development of complications (septic shock, renal failure, and disseminated intravascular coagulopathy); empiric monotherapy with glycopeptides (vs combination therapy with an aminoglycoside); and inadequate empiric treatment. " 09/01/2000 - "Some antibiotics, such as carbapenems, ceftriaxone, cefepime, glycopeptides, aminoglycosides and quinolones, do not have the propensity to provoke septic shock because their rapid bacterial activity induces mainly spheroplast or fragile spheroplast-like bacterial forms." 07/01/1999 - "Some antibiotics such as carbapenems, ceftriaxone, cefepime, glycopeptides, aminoglycosides and quinolones do not have the propensity to provoke septic shock because their rapid bactericidal activity induces mainly spheroplast or fragile spheroplast-like bacterial forms." Order ALL the reference details at left...
5.	Meningitis 02/08/2003 - "[Staphylococcus aureus meningitis with intermediate sensitivity to glycopeptides. " 05/01/1996 - "Glycopeptides which have excellent in vitro activity against the Gram-positive causal agents of meningitis unfortunately have a poor CSF penetration. " 10/01/1995 - "Bacterial glycopeptides induce enhanced blood-brain barrier permeability when they are present in the subarachnoid space during meningitis. " 09/01/1995 - "Use of glycopeptides in meningitis and the role of cerebrospinal fluid drainage are discussed. " 11/01/2007 - "The pathogen is naturally resistant to cephalosporins and some glycopeptides as well, therefore despite of syndromologic diagnosis of meningitis and initial therapy with 3rd generation cephalosporins according to the guidelines therapeutic failures with clinical consequences may occur." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Vancomycin
2.	linezolid (Zyvox)
3.	Peptides
4.	Penicillins (Penicillin)
5.	Teicoplanin
6.	beta-Lactams
7.	Cephalosporins (Cephalosporin Antibiotics)
8.	Fluoroquinolones
9.	quinupristin-dalfopristin (Synercid)
10.	temporin

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Aftercare (After-Treatment)
3.	Oral Administration
4.	Immunotherapy
5.	Artificial Respiration (Mechanical Ventilation)

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>